Chemotherapy News and Research

Latest Chemotherapy News and Research

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

PRPS1 gene associated with DFN2 identified by researchers

A gene associated with a rare form of progressive deafness in males has been identified by an international team of researchers funded by the National Institute on Deafness and Other Communication Disorders.

17 Dec 2009

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

GOLFING icon Seve Ballesteros yesterday (Monday 14th December) joined forces with Cancer Research UK in a bid to beat brain cancer. Seve said he was 'lucky to be alive and owed it all to important research many people have carried out in the past'.

17 Dec 2009

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Scientists in Sweden are reporting for the first time that a group of drugs used to treat heart failure shows promise for fighting colon cancer. The study is in ACS' Journal of Natural Products, a monthly publication. Colon cancer is the third most common cancer in the United States, with more than 150,000 cases diagnosed in the U.S. each year.

17 Dec 2009

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.

16 Dec 2009

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

FDA grants approval to market InterSol platelet additive solution

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution.

15 Dec 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

New stem cell based technology may eliminate brain cancer

UAB professors honored for scientific contributions and outstanding mentorship

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Brachytherapy for lung cancer

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Phase 2 clinical study of STA-9090 in NSCLC initiated

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

PRPS1 gene associated with DFN2 identified by researchers

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

FDA Advisory Committee votes against the approval of Tarceva

ODAC to review Cell Therapeutics' NDA for pixantrone

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

FDA grants approval to market InterSol platelet additive solution

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in